STAA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 125.00
EPS (TTM)$-0.42-10.5% YoY
Profit margin-7.2%HEALTHCARE
Market cap$1.44BSmall cap
Wall Street coverage
$29.67median target· current $40.11 (-26.0%)11 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 125.00
- PEG ratio
- 0.76
- P/B
- 4.09
- P/S (TTM)
- 4.96
- EV/EBITDA
- 89.08
Profitability & growth
- ROE (TTM)
- -6.0%
- Operating margin
- 18.7%
- Revenue growth YoY
- 119.6%
- Dividend yield
- —
- Beta
- 1.23
Last earnings
May 13, 2026 · Estimate $0.03 · Reported $0.10
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About STAAR Surgical Company
Company profileSTAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Classification
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 25510 COMMERCENTRE DRIVE, LAKE FOREST, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$1.44B
Shares outstanding$49.8M
52W high$35.87
52W low$15.59
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent